Search

Your search keyword '"Trasciatti S"' showing total 2 results
Start Over Author "Trasciatti S" Topic bone and bones
2 results on '"Trasciatti S"'

1. Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

Author

Fazzi R, Galimberti S, Testi R, Pacini S, Trasciatti S, Rosini S, and Petrini M

Subjects
Antigens, CD34 analysis, Blood Cells cytology, Blood Cells drug effects, Bone Marrow Cells cytology, Bone Marrow Cells drug effects, Cell Differentiation drug effects, Cell Lineage, Chemokine CCL4, Coculture Techniques, Colony-Forming Units Assay, Fetal Blood cytology, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Hematopoietic Cell Growth Factors physiology, Hematopoietic Stem Cells cytology, Humans, Leukemia pathology, Macrophage Inflammatory Proteins analysis, Myeloid Cells cytology, Organ Specificity, Proto-Oncogene Proteins c-kit analysis, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor analysis, Receptors, Interleukin-3 analysis, Stem Cell Factor pharmacology, Stromal Cells physiology, Tumor Cells, Cultured cytology, Bone Marrow physiology, Bone and Bones physiology, Endorphins pharmacology, Hematopoietic Stem Cells drug effects
Abstract

Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, peripheral blood and cord blood. Granulocyte-macrophage colony-forming unit (CFU) were significantly increased in OGP10-14-treated samples, while granulocyte-erythrocyte-monocyte-megakaryocyte CFU and burst-forming unit (BFU) erythroid were increased only in the cord blood test.Moreover, OGP10-14 preserves stem cells self renewal potential in long-term culture (LTC) initiating cells and acts directly on CD34+ enriched cells or by increasing activity of stem cell factor (SCF) and granulocyte-megakaryocyte colony-stimulating factor.

Published
2002
Full Text
View/download PDF

2. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.

Author

Fazzi R, Testi R, Trasciatti S, Galimberti S, Rosini S, Piras F, L'Abbate G, Conte A, and Petrini M

Subjects
Animals, Antigens, CD34 analysis, Antineoplastic Agents, Alkylating toxicity, Blood Cell Count, Bone Marrow Transplantation, Cells, Cultured, Colony-Forming Units Assay, Cyclophosphamide toxicity, Granulocyte Colony-Stimulating Factor pharmacology, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Histones, Male, Mice, Mice, Inbred ICR, Red-Cell Aplasia, Pure chemically induced, Bone Marrow Cells metabolism, Bone and Bones metabolism, Growth Substances pharmacology, Hematopoietic Stem Cells drug effects, Intercellular Signaling Peptides and Proteins, Leukocytes physiology, Osteoblasts drug effects, Peptides pharmacology, Red-Cell Aplasia, Pure prevention & control
Abstract

Osteogenic growth peptide (OGP) increases blood and bone marrow cellularity in mice, and enhances engraftment of bone marrow transplant. Carboxy-terminal pentapeptide (OGP10-14) holds several properties of full-length polypeptide. We evaluated whether synthetic OGP-derived pentapeptide (sOGP10-14) has some activity on peripheral blood cell recovery after cyclophosphamide-induced aplasia, and on stem cell mobilization. Peripheral blood stem cell (PBSC) mobilization was evaluated by administering granulocyte-colony stimulating factor (G-CSF) or sOGP10-14 after cyclophosphamide (CTX) injection. Haematological parameters and CD34/Sca-1 positive cells were sequentially evaluated. Colony-forming tests were performed in bone marrow cells from CTX-, G-CSF- and sOGP10-14-treated mice. sOGP10-14 was able to enhance band cells and monocyte recovery after cyclophosphamide administration. White blood cell (WBC) counts reached the maximum peak by day +10 but, on day +7, a significant recovery was already detected in sOGP10-14 treated mice. On day +10 the WBC increase in sOGP10-14-treated mice was comparable to that found in G-CSF treated ones. Moreover, CD34/Sca-1 positive early precursors were significantly mobilized by sOGP10-14 compared to the control group. In sOGP10-14-treated mice, the colony-forming unit-granulocyte-macrophage-megakaryocyte (GEMM-CFU) and burst-forming unit-erythroid (BFU-E) were significantly increased in bone marrow cells in comparison to mice treated with CTX only. These results suggest a central role of sOGP10-14 in bone and bone marrow interaction, and a possible role of sOGP10-14 as a mobilizing agent.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results